Latin-American consensus document on irritable bowel syndrome (Q44874984)

7 December 2017

1 reference

title

Latin-American consensus document on irritable bowel syndrome (English)

1 reference

7 December 2017

Valenzuela J

1

1 reference

7 December 2017

Alvarado J

2

1 reference

7 December 2017

Cohen H

3

1 reference

7 December 2017

Damiao A

4

1 reference

7 December 2017

Francisconi C

5

1 reference

7 December 2017

Frugone L

6

1 reference

7 December 2017

González JC

7

1 reference

7 December 2017

Hernández A

8

1 reference

7 December 2017

Iade B

9

1 reference

7 December 2017

Itaqui Lopes MH

10

1 reference

7 December 2017

Latorre R

11

1 reference

7 December 2017

Prado J

12

1 reference

7 December 2017

Moraes-Filho P

13

1 reference

7 December 2017

Schmulson M

14

1 reference

7 December 2017

Soifer L

15

1 reference

7 December 2017

Valdovinos MA

16

1 reference

7 December 2017

Vesco E

17

1 reference

7 December 2017

Zalar A

18

1 reference

7 December 2017

publication date

1 May 2004

1 reference

Gastroenterología y Hepatología

7 December 2017

published in

1 reference

7 December 2017

volume

27

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

325-343

1 reference

Towards positive diagnosis of the irritable bowel

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Comparison of bowel patterns in hispanics and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Survey of the AGA membership relating to patients with functional gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Irritable bowel syndrome in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Irritable bowel syndrome in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Irritable bowel syndrome: a technical review for practice guideline development

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Review article: visceral hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Review article: irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Regional cerebral activity in normal and pathological perception of visceral pain

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Chili pepper and rectal hyperalgesia in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Postinfectious irritable bowel syndrome1 1Abbreviations used in this paper: EC,_; IBS, irritable bowel syndrome; PI, postinfective

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Sexual and physical abuse in women with functional or organic gastrointestinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Gastrointestinal tract symptoms and self-reported abuse: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Patient‐perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Quality of life measurement in gastroenterology: what is available?

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Assessment of quality-of-life outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

What determines severity among patients with painful functional bowel disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Clinical economics review: irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

The economic impact of irritable bowel syndrome in a managed care setting

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Diagnostic value of the Manning criteria in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Diagnostic approach to the patient with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Site of pain from the irritable bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Variation of bowel habit in two population samples

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Non-colonic features of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Airway responsiveness to inhaled methacholine in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Comorbidity of fibromyalgia with medical and psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Systematic review on the management of irritable bowel syndrome in North America.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Panic disorder: Relationship to high medical utilization

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Treatment of irritable bowel syndrome: a review of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Estimation of per capita crude and dietary fiber supply in 38 countries

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Effect of bran, ispaghula, and inert plastic particles on gastric emptying and small bowel transit in humans: the role of physical factors

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Psyllium therapy in the irritable bowel syndrome. A double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Bran supplementation in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Irritable bowel syndrome: Assessment of psychological disturbance and its influence on the response to fibre supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Calcium polycarbophil compared with placebo in irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Double blind study of ispaghula in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Loperamide improves anal sphincter function and continence after restorative proctocolectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Controlled treatment trials in the irritable bowel syndrome: a critique.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Serotoninergic neuroenteric modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Serotonin mechanisms in chemotherapy-induced emesis in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Management of the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

AGA technical review on irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Long term benefits of hypnotherapy for irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

New drugs in the management of the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970470-1

7 January 2021

10.1016/S0210-5705(03)70470-1

Identifiers

DOI

1 reference

7 December 2017

1 reference